レサス・マカクは,ピオグリタゾンに反応する可逆性血管機能不全による代謝症候群を発症します
Xiuqin Zhang1, Rongli Zhang, Susanne Raab
1Institute of Molecular Medicine, Peking University, No.5 Yiheyuan Rd, Haidian District, Beijing 100871, China.
Circulation
|June 22, 2011
まとめ
メタボリックシンドローム (MetS) のコンポーネントは, metabolic と cardiovascular の問題をリンクして,一緒に追跡します. ピオグリタゾン治療は血管機能不全を逆転させ,共用メカニズムとMetSの早期介入をサポートしました.
科学分野:
- メタボリックと心臓血管研究
- 人間の病気の霊長類のモデル
- 薬理学的介入 薬理学的介入
背景:
- メタボリックシンドローム (MetS) は,肥満,高血圧,脂質不全,およびインスリン抵抗性を含む状態のクラスターです.
- MetSの根本的な病理生理学は,共有されたメカニズムであろうと,偶然の危険因子であろうと,依然として議論されている.
研究 の 目的:
- MetS発達の過程で代謝と心血管の要素の共出現を調査する.
- MetSと血管機能不全の間のメカニズム的なリンクを探求する.
- MetSにおけるピオグリタゾンの治療の可能性を評価する.
主な方法:
- MetSに罹患しやすい rhesus macaqueの18か月の特定とモニタリング.
- 流動媒介の膨張を含む代謝および心血管のパラメータの評価.
- MetS動物をPPARγアゴニストであるピオグリタゾンで治療する.
主要な成果:
- MetSの成分は, rhesus macaquesの疾患進行中に一緒に追跡された.
- MetSはフローメディエーションによる膨張の有意な障害と関連しており,血管機能不全を示唆しています.
- ピオグリタゾン治療は,不脂血症とインスリン抵抗性を改善し,血管機能を完全に回復させました.
結論:
- 共有された病理生理学的メカニズムは,メトス発症と心血管合併症の根底にある.
- MetSコンポーネントをターゲットにした早期介入は有益です.
- 非人間霊長類のモデルは,METS研究と翻訳研究に価値があります.
関連する概念動画
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.